A Phase 1/2 interventional study of HeXell-2020 in Coronary Artery Disease, sponsored by Hexun Biosciences Co., LTD.. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Hexun Biosciences Co., LTD. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Coronary Artery Disease with a site in Taiwan — 12 open to participants now, 16 under way, 2 of them phase 3. Coronary Artery Disease · Taiwan.
Among the 68 studies in Coronary Artery Disease with a site in Taiwan, this one is the 47th largest by planned enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2026, is the only one in phase 1/2, reaches primary completion later than 9 of the 15 other live ones, and was the 65th registered.
4,862 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →12 of the 68 studies in Coronary Artery Disease with a site in Taiwan are open now. Recruiting first, the newest first:
Siou-Pin Huang · Sites in Taiwan
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 20+
CSL Behring · Sites in Taiwan, United States, Argentina and 32 more countries
Ages 18+
Seung-Jung Park · Sites in Taiwan, Hong Kong, India and 2 more countries
Ages 20+
Weill Medical College of Cornell University · Sites in Taiwan, United States, Australia and 23 more countries
Ages 18+ · Women only
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 12 · Phase 4 7
First in 2004; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 39 is below the median of 124 across 3,010 interventional studies indexed under Coronary Artery Disease.
Median enrollment 172 across the 51 interventional studies, 652 across the 16 observational. Of the 33 that completed or were terminated, 11 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 68 have an industry lead sponsor. The 10 most frequent:
Hexun Biosciences Co., LTD. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Hexun Biosciences Co., LTD. has 1 study filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
5 of the studies in Coronary Artery Disease with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07469397National Taiwan University HospitalPreliminary Exploration of Factors Affecting Complete Hemostasis and Supine Time After Removal of Femoral Arterial Sheath in ICU Patients | 2026-12-31 |
| NCT05846893B. Braun Medical Industries Sdn. Bhd.Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease | 2027-05 |
| NCT07649330Siou-Pin HuangEffects of Myofascial Release on Cardiac Patients After Median Sternotomy | 2027-05 |
| NCT07195968National Taiwan University HospitalComparative Analysis of NTG-Pd/Pa and Saline-Pd/Pa (CANS) | 2027-05-31 |
| NCT05829889Seung-Jung ParkFractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease | 2027-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 68 studies in Coronary Artery Disease with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase I/IIa study to investigate the safety, tolerability, and preliminary effectiveness of HeXell-2020 in patients with stable coronary artery disease (CAD). HeXell-2020 is an investigational drug product consisting of allogenic umbilical cord mesenchymal stem cells (UCMSCs) as the drug substance. All enrolled and eligible subjects will receive HeXell-2020 treatment.
Coronary artery disease (CAD) is the most common form of heart disease and a leading cause of mortality worldwide. It is a manifestation of myocardial ischemia, a condition resulting from insufficient blood flow to the myocardial tissue. CAD occurs when the coronary arteries become progressively narrowed and stiffened due to atherosclerosis-the accumulation of cholesterol, lipids, and plaque along the inner arterial walls. Narrowed blood vessels and increased shear stress may contribute to plaque destabilization, vessel outward remodeling, as well as increased pro-inflammatory cytokines production, leading to advanced atherosclerosis. As the disease advances, this narrowing impairs coronary blood flow, causing permanent heart damage. Over time, CAD can progressively weaken the heart muscle, contributing to heart failure.
Mesenchymal stem cells (MSC) become a potential therapeutic tool for treating cardiovascular diseases due to their capabilities in tissue repair, anti-oxidation, immune-modulation and anti-inflammatory. Intravenous infusion of HeXell-2020, the allogenic umbilical cord MSC, in an atherosclerotic rat model improved blood glucose tolerance, LDL cholesterol levels, and the severity of aortic arch stenosis. Additionally, results further demonstrated significant improvement in atherosclerotic lesions caused by fat deposition at the aortic arch and descending aorta after the treatment. Although the mode of actions of MSCs in CADs have not been fully elucidated, these nonclinical results, together with the established immunomodulatory and anti-inflammatory effects of MSCs, are supportive for the rationale of HeXell-2020 in treating patients with CAD.
This study is composed of two phases, Phase I and Phase IIa. In Phase I, two cohorts were designed following traditional 3+3 scheme to define recommended phae 2 dose (RP2D). In Phase IIa, 22 evaluable subjects are estimated. Safety and efficacy will be evaluated through follow-up visit over one year.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All male patients and female patients with (between puberty and 2 years after menopause) should use at least any one of the appropriate methods shown below, during dosing and for at least 4 weeks after stopping study treatment.
d.1. Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception. Please refer to 8.2 Prohibited Treatments for detailed information.
d.2. Placement of an intrauterine device (IUD) or intrauterine system (IUS). d.3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps).
Exclusion Criteria:
Patient is schedule to [or has received within 180 days prior to Screening Visit] undergo the following coronary revascularization throughout the study period:
Patient with evidence of medical condition as follows,
Evidence of inadequate hematopoietic, hepatic, and renal function as determined by any one of the following laboratory requirements:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 1 :single arm. two cohort. cohort 1: HeXell-2020 will be administered by intravenous once every two weeks, and a total of 3 doses. cohort 2: HeXell-2020 will be administered by intravenous once every two weeks, and a total of 6 doses. Phase 2a: Single arm.
Drug: HeXell-2020
Phase I Cohort 1: HeXell-2020 with a total of 3 doses, 9x10\^7 cells/dose. Phase I Cohort 2: HeXell-2020 with a total of 6 doses, 9x10\^7 cells/dose. Phase IIa: RP2D from phase I.
Incidence of TEAE, SAE and SUSAR over the study
To evaluate the number of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), suspected and unexpected serious adverse reactions (SUSARs) over the study period,
Time frame: Within the first year after cell transplantaion
To determine the recommended phase II dose (RP2D) in Phase I study
To determination RP2D, number and proportion of subjects having experienced DLTs will be presented and the RP2D should be determined on the indicated dose at which ≤ 1 patient experiences DLT out of 6 patients who have been DLT evaluated.
Time frame: Within the first year after cell transplantaion
Change in myocardial perfusion defect severity under the rest acquisition and pharmacological stress of dipyridamole in Phase IIa study
Measured by SPECT with thallium-201 from baseline. The SRS, SSS and SDS are three variables used to measure cardiac perfusion and ischemia.
Time frame: Before first dosing and at 12 months post cell transplantaion
Time to the first occurrence of major adverse cardiovascular events (MACEs)
Including AMI, stroke, cardiovascular mortality, and hospitalization for unstable angina or revascularization procedures, from the date of the first treatment will be analyzed by Kaplan-Meier method.
Time frame: From the date of the first treatment until the first occurrence of MACE, death, or study cut-off point, unless the subject has withdrawn consent for all contacts or is loss of follow-up, whichever came first, assessed up to 24 months.
Change in the evaluation result of CCTA from baseline
The stenosis percent of the different coronary segments, using the 17-segment model.
Time frame: Before first dosing and at 3, 6 months post cell transplantation
Change from baseline in echocardiographic measures.
Ventricular remodeling: including LVEF in percentage, global longitudinal strain (GLS) in percentage.
Time frame: Before first dosing and at 3, 6, 12 months post cell transplantation
Change in functional class of angina by using CCS angina classification from baseline.
Change in functional class of angina by using CCS angina classification will be summarized descriptively by visit
Time frame: Before first dosing, and 1, 3, 6 , 12 months post cell transplantation
Change in the 6-minute walk test (6-MWT) from baseline.
The 6-MWT measures the distance walked on level ground in 6 minutes.
Time frame: Before first dosing and 6, 12 months post cell transplantation
Change in serum levels of amino-terminal pro-brain natriuretic peptide (NT pro-BNP) and high sensitivity cardiac troponin (hs-cTn) from baseline.
Change in serum levels of NT pro-BNP and hs-cTn from baseline will be summarized descriptively.
Time frame: Before first dosing, and 1, 3, 6 , 12 months post cell transplantation
Change in quality of life using the Seattle Angina Questionnaire (SAQ) from baseline.
The SAQ, a 19-item self-administered questionnaire measuring 5 dimensions of CAD: physical limitation, anginal stability, anginal frequency, treatment satisfaction and disease perception will be used to assess the functional change of CAD in HeXell-2020 administered patients.
Time frame: Before first dosing, and 1, 3, 6 , 12 months post cell transplantation
Change from baseline in echocardiographic measures.
Myocardial performance \[including isovolumic relaxation time (IVRT), isovolumic contraction time (IVCT), LV ejection time (ET), and myocardial performance index (MPI or Tei Index)\]\[MPI= (IVCT+IVRT)/ET\]
Time frame: Before first dosing and at 3, 6, 12 months post cell transplantation
Change in the evaluation result of CCTA from baseline
Severity of stenosis assessed by 2022 Coronary Artery Disease Reporting and Data System (CAD-RADSTM 2.0), ranging from CAD-RADS 0 for absence of any plaque or stenosis to CAD-RADS 5 for the presence of at least 1 totally occluded coronary artery.
Time frame: Before first dosing and at 3, 6 months post cell transplantation
Change in the evaluation result of CCTA from baseline
Coronary artery calcium score (CACS, as per Agatston method, J Am Coll Cardiol. 1990;15:827-32), higher scores mean a worse outcome.
Time frame: Before first dosing and at 3, 6 months post cell transplantation
Change from baseline in echocardiographic measures.
Ventricular remodeling: LV end-diastolic volume (EDV) in mL, and end-systolic volume (ESV) in mL, stroke volume (SV in ), calculated by EDV - ESV ( mL)
Time frame: Before first dosing and at 3, 6, 12 months post cell transplantation.
Change from baseline in echocardiographic measures.
Ventricular remodeling: LV internal diameter in diastole and systole (LVIDd and LVIDs in mm), interventricular septum diameter (IVSD in mm), posterior wall thickness (PWT in mm), anteroseptal wall thickness (ASWT in mm)
Time frame: Before first dosing and at 3, 6, 12 months post cell transplantation.
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Dec 2028, 28 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: start Dec 2025 → Aug 2026, primary completion Dec 2027 → Dec 2028 and completion Jul 2028 → Jul 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hexun Biosciences Co., LTD.